These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29989312)

  • 21. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A; Al-Makki A; Sutton J; Shepler B
    Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Floege J
    Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL; Plosker GL
    Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders.
    Sprague SM; Reddy G; Jermasek D; Gupta P
    Am J Nephrol; 2023; 54(5-6):219-223. PubMed ID: 37231835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles.
    Ogata H; Takeshima A; Ito H
    Expert Opin Drug Saf; 2022 Jul; 21(7):947-955. PubMed ID: 35180026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
    Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
    Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
    J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
    Koiwa F; Sato Y
    Clin Calcium; 2009 Feb; 19(2):198-204. PubMed ID: 19182359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Iron-based Phosphate Binders for ESRD Patients].
    Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
    Martin P; Wang P; Robinson A; Poole L; Dragone J; Smyth M; Pratt R
    Am J Kidney Dis; 2011 May; 57(5):700-6. PubMed ID: 21354682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate.
    Navarrete JE; Ajiboye O; Lea JI
    Perit Dial Int; 2024 Mar; 44(2):133-140. PubMed ID: 37691436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y; Masumoto A; Moribata M; Shigemathu T
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of phosphate binder in predialysis patients].
    Taniguchi M
    Clin Calcium; 2009 Feb; 19(2):229-35. PubMed ID: 19182364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sucroferric oxyhydroxide, a novel iron-based phosphate binder. Which current use in dialysis patients?].
    Bataille P; Delattre V; Daroux M
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S103-S108. PubMed ID: 28577730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Phosphate binder up to date].
    Shigematsu T; Sakaguchi T; Orita H
    Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study.
    Neradova A; Schumacher SP; Hubeek I; Lux P; Schurgers LJ; Vervloet MG
    BMC Nephrol; 2017 May; 18(1):149. PubMed ID: 28464802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.